Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Products under Develo... | 8 | 1 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Products under Devel... | 9 | 1 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Products under Devel... | 10 | 2 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Pipeline Products Gl... | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Products under Devel... | 14 | 4 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Companies Involved i... | 24 | 7 |
| Basilea Pharmaceutica AG | 24 | 1 |
| Boehringer Ingelheim GmbH | 25 | 1 |
| Bristol-Myers Squibb Company | 26 | 1 |
| CompleGen, Inc. | 27 | 1 |
| Novartis AG | 28 | 2 |
| TopiVert Ltd | 30 | 1 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Drug Profiles | 31 | 24 |
| CCT-196969 Drug Profile | 31 | 1 |
| CCT-241161 Drug Profile | 32 | 1 |
| CGX-1079 Drug Profile | 33 | 1 |
| dasatinib Drug Profile | 34 | 3 |
| nintedanib Drug Profile | 37 | 9 |
| pazopanib hydrochloride Drug Profile | 46 | 7 |
| pazopanib hydrochloride + pembrolizumab Drug Profile | 53 | 1 |
| TOP-1630 Drug Profile | 54 | 1 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Dormant Projects | 55 | 3 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Discontinued Products | 58 | 1 |
| Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 2.7.10.2) Featured News &Pres... | 59 | 17 |
| Jun 30, 2016: INMARK now enrolling: first study to evaluate the effect of OFEV (nintedanib) on biomarkers reflecting the underlying fibrotic process in IPF patients | 59 | 1 |
| Jun 29, 2016: Leukemia drug shows potential for rarer type of ovarian cancer | 60 | 1 |
| Jun 27, 2016: New analysis of INPULSIS trials demonstrates efficacy of OFEV (nintedanib) across a range of IPF patients using broader diagnostic criteria | 61 | 1 |
| Jun 09, 2016: Bristol-Myers Squibb to Present Data on Sprycel (dasatinib) at the 21st Congress of the European Hematology Association | 62 | 1 |
| May 16, 2016: New Presentations at ATS 2016 Reinforce OFEV (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with idiopathic pulmonary fibrosis | 63 | 1 |
| May 16, 2016: TopiVert completes preclinical development with TOP1630 for dry eye disease | 64 | 1 |
| May 09, 2016: LUME-Meso trial enrols first patient: Boehringer Ingelheim s new pivotal study investigating nintedanib for the treatment of malignant pleural mesothelioma | 65 | 1 |
| Feb 25, 2016: New analysis confirms OFEV (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations | 65 | 2 |
| Jan 27, 2016: NICE recommends nintedanib for idiopathic pulmonary fibrosis | 67 | 1 |
| Jan 26, 2016: Boehringer Ingelheim is Pleased to Welcome Green Light from the National Institute for Health and Care Excellence (NICE) for Its Medicine for Rare Lung Disease | 67 | 1 |
| Dec 14, 2015: Initiation of first multinational study to evaluate safety of OFEV (nintedanib) with add-on of pirfenidone in patients with IPF | 67 | 1 |
| Dec 08, 2015: New Phase III study of nintedanib in people with systemic sclerosis and lung fibrosis | 68 | 1 |
| Nov 13, 2015: New Analyses Further Add to the Efficacy and Safety Profile of OFEV (nintedanib) in Idiopathic Pulmonary Fibrosis | 69 | 2 |
| Oct 26, 2015: New Analyses Showed Consistent Efficacy of OFEV (nintedanib) Across Various Patient Populations with Idiopathic Pulmonary Fibrosis | 71 | 1 |
| Sep 29, 2015: New data demonstrate sustained long-term efficacy of OFEV on slowing disease progression and safety in patients with IPF | 72 | 4 |
| Appendix | 76 | 2 |
| Methodology | 76 | 1 |
| Coverage | 76 | 1 |
| Secondary Research | 76 | 1 |
| Primary Research | 76 | 1 |
| Expert Panel Validation | 76 | 1 |
| Contact Us | 76 | 1 |
| Disclaimer | 77 | 1 |